GTBP实时信号 | 通过Getagraph.com最大化利润

Live Chart Being Loaded With Signals

Commentary (1 Jun 2024 @ 04:00):

Stats
今日成交量	17 132.00
平均成交量	1.37M
市值	8.09M
EPS	$0 ( 2024-05-20 )
下一个收益日期	( $-2.70 ) 2024-08-05
Last Dividend	$0 ( N/A )
Next Dividend	$0 ( N/A )
P/E	-0.530
ATR14	$0.0430 (1.15%)

Insider Trading

Date	Person	Action	Amount	type
2023-08-11	Breen Michael Martin	Buy	200 000	Common Stock
2023-08-11	Ohri Manu	Buy	200 000	Common Stock
2023-08-11	Ohri Manu	Buy	200 000	Common Stock
2023-08-11	Ohri Manu	Sell	200 000	Common Stock
2023-06-16	Casamento Charles J	Buy	500 000	Option to purchase Common Stock

INSIDER POWER
83.14
Last 90 transactions
Buy: 52 855 774 \| Sell: 22 501 893

音量相关性

長: 0.10 (neutral)

短: -0.66 (moderate negative)

Signal:(47.71) Neutral

GT Biopharma, Inc. 相关性

10 最正相关

10 最负相关

你知道吗？

相关性是描述两个变量之间关系的统计指标。它的取值范围为-1到1，其中-1表示完全负相关（一个变量增加，另一个变量减少），1表示完全正相关（一个变量增加，另一个变量也增加），0表示没有相关性（变量之间没有关系）。

相关性可用于分析任何两个变量之间的关系，而不仅仅是股票。它通常用于金融、经济学、心理学等领域。

GT Biopharma, Inc. 相关性 - 货币/商品

0.33
( neutral )

-0.03
( neutral )

0.00
( neutral )

0.35
( neutral )

-0.30
( neutral )

GT Biopharma, Inc. 财务报表

Annual	2023
营收:	$0
毛利润:	$0 (0.00 %)
EPS:	$-5.64

FY	2023
营收:	$0
毛利润:	$0 (0.00 %)
EPS:	$-5.64

FY	2022
营收:	$0
毛利润:	$0 (0.00 %)
EPS:	$-19.30

FY	2021
营收:	$0.00
毛利润:	$0.00 (0.00 %)
EPS:	$-2.06

Financial Reports:

No articles found.

GT Biopharma, Inc. Options Data

Calls

Contract Name	Last Trade Date (EDT)	Strike	Last Price	Bid	Ask	Change	% Change	Volume	Open Interest	Implied Volatility	Strike Date
No data available

Puts

Contract Name	Last Trade Date (EDT)	Strike	Last Price	Bid	Ask	Change	% Change	Volume	Open Interest	Implied Volatility	Strike Date
No data available

GT Biopharma, Inc.

GT Biopharma, Inc., a clinical stage biopharmaceutical company, focuses on the development and commercialization of immuno-oncology products based on its proprietary Tri-specific Killer Engager (TriKE) fusion protein immune cell engager technology platform. It develops GTB-3550, a single-chain tri-specific recombinant fusion protein conjugate that is in Phase I/II clinical trial for the treatment of myelodysplastic syndromes, refractory/relapsed acute myeloid leukemia or advanced systemic mastocytosis, and CD33+ malignancies. The company is developing GTB-3650, which is in preclinical studies that target CD33 on the surface of myeloid leukemias; and GTB-5550 that is in preclinical studies for treating patients with B7-H3 positive solid tumors. GT Biopharma, Inc. has a co-development partnership agreement with Altor BioScience Corporation for the clinical development of a 161533 TriKE fusion protein for cancer therapies; and a license agreement with the Regents of the University of Minnesota to develop and commercialize cancer therapies using TriKE technology. The company was formerly known as OXIS International, Inc. and changed its name to GT Biopharma, Inc. in July 2017. GT Biopharma, Inc. was incorporated in 1965 and is based in Brisbane, California.